'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins

 
• By Mandy Jackson
  
Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D